Active substance
Results for the substance trastuzumab deruxtecan
1 result
About this active substance
Trastuzumab deruxtecan is an antibody-drug conjugate used in the treatment of metastatic or inoperable HER2-positive breast cancer and other HER2-positive cancers. It combines trastuzumab, a monoclonal antibody targeting the HER2 receptor, with deruxtecan, a potent cytotoxic agent that inhibits cell division.
Trastuzumab deruxtecan works by binding to the HER2 receptor on the surface of tumor cells, delivering deruxtecan directly into cancer cells and destroying them. It is administered intravenously, usually once every three weeks, with the dose adjusted based on the patient's body weight.
Common side effects include nausea, vomiting, fatigue, alopecia, and neutropenia. In rare cases, severe adverse reactions such as interstitial lung toxicity or heart failure may occur. Careful monitoring of the patient is essential to promptly identify and manage these reactions.
Trastuzumab deruxtecan is an advanced therapeutic option for patients with HER2-positive cancer, offering a targeted and effective approach to disease control and prolonged survival.
Trastuzumab deruxtecan works by binding to the HER2 receptor on the surface of tumor cells, delivering deruxtecan directly into cancer cells and destroying them. It is administered intravenously, usually once every three weeks, with the dose adjusted based on the patient's body weight.
Common side effects include nausea, vomiting, fatigue, alopecia, and neutropenia. In rare cases, severe adverse reactions such as interstitial lung toxicity or heart failure may occur. Careful monitoring of the patient is essential to promptly identify and manage these reactions.
Trastuzumab deruxtecan is an advanced therapeutic option for patients with HER2-positive cancer, offering a targeted and effective approach to disease control and prolonged survival.